JENSCARE SCIENTIFIC CO., LTD. Jenscare Scientific Co., Ltd. Share Price
Equities
9877
CNE100005KC9
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.94 HKD | +3.35% |
|
+26.34% | -77.75% |
| Sales 2023 | - | Sales 2024 * | 214M 29.54M 231M 2.36B | Capitalization | 1.91B 264M 2.06B 21.04B |
|---|---|---|---|---|---|
| Net income 2023 | -372M -51.38M -401M -4.1B | Net income 2024 * | -205M -28.32M -221M -2.26B | EV / Sales 2023 | - |
| Net cash position 2023 * | - 0 0 0 | Net cash position 2024 * | - 0 0 0 | EV / Sales 2024 * | 8.92 x |
| P/E ratio 2023 |
-22.7
x | P/E ratio 2024 * |
-9.34
x | Employees | 376 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 64.73% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.35% | ||
| 1 week | +26.34% | ||
| Current month | -8.69% | ||
| 1 month | -1.20% | ||
| 3 months | -66.35% | ||
| 6 months | -77.29% | ||
| Current year | -77.75% |
1 week
3.86
5.24
1 month
3.175.55
Current year
3.1721.50
1 year
3.1745.00
3 years
3.1794.70
5 years
3.1794.70
10 years
3.1794.70
| Managers | Title | Age | Since |
|---|---|---|---|
Shi Wen Lv
CEO | Chief Executive Officer | 55 | 31/12/12 |
Yuan Yuan Li
DFI | Director of Finance/CFO | 38 | 30/11/20 |
Fei Pan
DFI | Director of Finance/CFO | 39 | 31/12/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shou Kang Lin
BRD | Director/Board Member | 60 | 30/04/21 |
Fei Pan
DFI | Director of Finance/CFO | 39 | 31/12/20 |
Shi Wen Lv
CEO | Chief Executive Officer | 55 | 31/12/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/05/24 | 4.94 | +3.35% | 403 800 |
| 30/04/24 | 4.78 | +0.63% | 5,701,000 |
| 29/04/24 | 4.75 | +0.42% | 3,567,400 |
| 26/04/24 | 4.73 | +12.89% | 10,237,000 |
| 25/04/24 | 4.19 | -10.09% | 7,005,800 |
Delayed Quote Hong Kong S.E., May 02, 2024 at 09:08 am
More quotes
Jenscare Scientific Co Ltd is a China-based company mainly engaged in the manufacturing and research and development of medical devices. The Company develops interventional products for the treatment of structural heart disease. The Company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The Company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure. The Company mainly conducts its businesses in the domestic market.
Calendar
27/08/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.575
CNY
Average target price
39.39
CNY
Spread / Average Target
+761.08%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -77.75% | 255M | |
| +9.07% | 125B | |
| -8.61% | 10.63B | |
| +2.17% | 8.92B | |
| +23.48% | 7.39B | |
| +32.13% | 4.96B | |
| +7.84% | 3.41B | |
| -6.94% | 3.04B | |
| -5.07% | 2.23B | |
| -4.22% | 2.13B |
- Stock Market
- Equities
- 9877 Stock
